• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于异烟酰哌啶的首创类凝血酶和胆碱酯酶双重抑制剂,具有治疗阿尔茨海默病的潜力。

First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease.

机构信息

Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy.

出版信息

Molecules. 2021 Aug 27;26(17):5208. doi: 10.3390/molecules26175208.

DOI:10.3390/molecules26175208
PMID:34500640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8434007/
Abstract

Recently, the direct thrombin (thr) inhibitor dabigatran has proven to be beneficial in animal models of Alzheimer's disease (AD). Aiming at discovering novel multimodal agents addressing thr and AD-related targets, a selection of previously and newly synthesized potent thr and factor Xa (fXa) inhibitors were virtually screened by the Multi-fingerprint Similarity Searching aLgorithm (MuSSeL) web server. The -phenyl-1-(pyridin-4-yl)piperidine-4-carboxamide derivative , which has already been experimentally shown to inhibit thr with a K value of 6 nM, has been flagged by a new, upcoming release of MuSSeL as a binder of cholinesterase (ChE) isoforms (acetyl- and butyrylcholinesterase, AChE and BChE), as well as thr, fXa, and other enzymes and receptors. Interestingly, the inhibition potency of was predicted by the MuSSeL platform to fall within the low-to-submicromolar range and this was confirmed by experimental K values, which were found equal to 0.058 and 6.95 μM for AChE and BChE, respectively. Thirty analogs of were then assayed as inhibitors of thr, fXa, AChE, and BChE to increase our knowledge of their structure-activity relationships, while the molecular determinants responsible for the multiple activities towards the target enzymes were rationally investigated by molecular cross-docking screening.

摘要

最近,直接凝血酶(thr)抑制剂达比加群已被证明对阿尔茨海默病(AD)的动物模型有益。为了发现针对 thr 和 AD 相关靶点的新型多模式试剂,通过 Multi-fingerprint Similarity Searching aLgorithm(MuSSeL)网络服务器对先前和新合成的强效 thr 和因子 Xa(fXa)抑制剂进行了虚拟筛选。-苯基-1-(吡啶-4-基)哌啶-4-甲酰胺衍生物 ,已通过实验证明可抑制 thr,其 K 值为 6 nM,已被 MuSSeL 的新版本标记为胆碱酯酶(ChE)同工型(乙酰胆碱酯酶和丁酰胆碱酯酶,AChE 和 BChE)以及 thr、fXa 和其他酶和受体的结合物。有趣的是,MuSSeL 平台预测 的抑制效力在低至亚微摩尔范围内,这通过实验 K 值得到了证实,AChE 和 BChE 的 K 值分别为 0.058 和 6.95 μM。然后,对 的 30 种类似物进行了 thr、fXa、AChE 和 BChE 抑制剂的测定,以增加我们对其结构-活性关系的了解,同时通过分子交叉对接筛选合理研究了负责针对靶酶的多种活性的分子决定因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/382c0ef30c16/molecules-26-05208-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/bd4923473553/molecules-26-05208-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/2c5edffeaa2a/molecules-26-05208-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/4b9832c47803/molecules-26-05208-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/e01b93d9ee5e/molecules-26-05208-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/f8dc8434f9d5/molecules-26-05208-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/750402338570/molecules-26-05208-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/382c0ef30c16/molecules-26-05208-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/bd4923473553/molecules-26-05208-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/2c5edffeaa2a/molecules-26-05208-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/4b9832c47803/molecules-26-05208-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/e01b93d9ee5e/molecules-26-05208-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/f8dc8434f9d5/molecules-26-05208-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/750402338570/molecules-26-05208-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eecb/8434007/382c0ef30c16/molecules-26-05208-g005.jpg

相似文献

1
First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease.基于异烟酰哌啶的首创类凝血酶和胆碱酯酶双重抑制剂,具有治疗阿尔茨海默病的潜力。
Molecules. 2021 Aug 27;26(17):5208. doi: 10.3390/molecules26175208.
2
Assessing the Role of a Malonamide Linker in the Design of Potent Dual Inhibitors of Factor Xa and Cholinesterases.评估丙二酰胺连接子在设计强效因子 Xa 和胆碱酯酶双重抑制剂中的作用。
Molecules. 2022 Jul 2;27(13):4269. doi: 10.3390/molecules27134269.
3
Design and Synthesis of Novel Arylisoxazole-Chromenone Carboxamides: Investigation of Biological Activities Associated with Alzheimer's Disease.新型芳基异噁唑-色满酮类羧酸酰胺的设计与合成:与阿尔茨海默病相关的生物活性研究。
Chem Biodivers. 2020 May;17(5):e1900746. doi: 10.1002/cbdv.201900746. Epub 2020 Apr 15.
4
Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.用于阿尔茨海默病治疗的具有双重抑制乙酰胆碱酯酶和β淀粉样蛋白1-42聚集活性的新型哌啶衍生物的合成、体外测定及分子模拟
Bioorg Med Chem. 2007 Oct 15;15(20):6596-607. doi: 10.1016/j.bmc.2007.07.003. Epub 2007 Jul 25.
5
Search for new multi-target compounds against Alzheimer's disease among histamine H receptor ligands.寻找组胺 H 受体配体中针对阿尔茨海默病的新型多靶化合物。
Eur J Med Chem. 2020 Jan 1;185:111785. doi: 10.1016/j.ejmech.2019.111785. Epub 2019 Oct 17.
6
N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.N-烷基哌啶氨基甲酸酯类作为潜在的抗阿尔茨海默病药物。
Eur J Med Chem. 2020 Jul 1;197:112282. doi: 10.1016/j.ejmech.2020.112282. Epub 2020 Apr 15.
7
Synthesis of novel carboxamide- and carbohydrazide-benzimidazoles as selective butyrylcholinesterase inhibitors.新型羧酰胺基和碳酰肼基苯并咪唑的合成及其作为选择性丁酰胆碱酯酶抑制剂的研究。
Mol Divers. 2022 Oct;26(5):2863-2876. doi: 10.1007/s11030-022-10476-8. Epub 2022 Jul 2.
8
Design, synthesis, biological evaluation, and molecular dynamics of novel cholinesterase inhibitors as anti-Alzheimer's agents.新型乙酰胆碱酯酶抑制剂的设计、合成、生物评价及作为抗阿尔茨海默病药物的分子动力学研究。
Arch Pharm (Weinheim). 2019 Jul;352(7):e1800352. doi: 10.1002/ardp.201800352. Epub 2019 May 28.
9
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.双环和三环系统的喹诺利定衍生物作为乙酰胆碱酯酶和丁酰胆碱酯酶的有效抑制剂,具有治疗阿尔茨海默病的潜力。
Eur J Med Chem. 2011 Jun;46(6):2170-84. doi: 10.1016/j.ejmech.2011.02.071. Epub 2011 Mar 5.
10
Microwave-Assisted Synthesis of (Piperidin-1-yl)quinolin-3-yl)methylene)hydrazinecarbothioamides as Potent Inhibitors of Cholinesterases: A Biochemical and In Silico Approach.微波辅助合成(哌啶-1-基)喹啉-3-基)亚甲基)肼甲硫酰胺作为胆碱酯酶的有效抑制剂:一种生化和计算方法。
Molecules. 2021 Jan 27;26(3):656. doi: 10.3390/molecules26030656.

引用本文的文献

1
Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal.小分子药物治疗长新冠相关血管损伤和异常血栓形成:基于专利的评估。
Viruses. 2024 Mar 14;16(3):450. doi: 10.3390/v16030450.
2
Investigation on Novel 2-Benzylideneindan-1-One-Based Photoswitches with AChE and MAO-B Dual Inhibitory Activity.新型 2-亚苄基茚满-1-酮类化合物的设计、合成及对 AChE 和 MAO-B 的双重抑制活性研究
Molecules. 2023 Aug 3;28(15):5857. doi: 10.3390/molecules28155857.
3
Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer's Disease.

本文引用的文献

1
Alzheimer disease.阿尔茨海默病。
Nat Rev Dis Primers. 2021 May 13;7(1):33. doi: 10.1038/s41572-021-00269-y.
2
Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.阿尔茨海默病:使用凝血酶抑制剂达比加群酯治疗的合理性。
Int J Mol Sci. 2021 Apr 30;22(9):4805. doi: 10.3390/ijms22094805.
3
Vascular Hypothesis of Alzheimer Disease: Topical Review of Mouse Models.阿尔茨海默病的血管假说:小鼠模型的专题综述。
直接口服抗凝剂(DOACs)用于靶向治疗凝血酶,凝血酶是阿尔茨海默病脑血管和神经元功能障碍的关键介质。
Biomedicines. 2022 Aug 4;10(8):1890. doi: 10.3390/biomedicines10081890.
4
Assessing the Role of a Malonamide Linker in the Design of Potent Dual Inhibitors of Factor Xa and Cholinesterases.评估丙二酰胺连接子在设计强效因子 Xa 和胆碱酯酶双重抑制剂中的作用。
Molecules. 2022 Jul 2;27(13):4269. doi: 10.3390/molecules27134269.
5
Identification of Potential Targets Linked to the Cardiovascular/Alzheimer's Axis through Bioinformatics Approaches.通过生物信息学方法识别与心血管/阿尔茨海默病轴相关的潜在靶点。
Biomedicines. 2022 Feb 6;10(2):389. doi: 10.3390/biomedicines10020389.
Arterioscler Thromb Vasc Biol. 2021 Apr;41(4):1265-1283. doi: 10.1161/ATVBAHA.120.311911. Epub 2021 Feb 25.
4
Anticoagulants for Treatment of Alzheimer's Disease.抗凝血剂治疗老年痴呆症。
J Alzheimers Dis. 2020;77(4):1373-1382. doi: 10.3233/JAD-200610.
5
Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer's Disease.凝血酶,神经血管界面处凝血、炎症和神经毒性的介质:对阿尔茨海默病的影响。
Front Neurosci. 2020 Jul 24;14:762. doi: 10.3389/fnins.2020.00762. eCollection 2020.
6
Multitarget Therapeutic Strategies for Alzheimer's Disease: Review on Emerging Target Combinations.阿尔茨海默病的多靶点治疗策略:新兴靶点组合综述。
Biomed Res Int. 2020 Jun 30;2020:5120230. doi: 10.1155/2020/5120230. eCollection 2020.
7
N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.N-烷基哌啶氨基甲酸酯类作为潜在的抗阿尔茨海默病药物。
Eur J Med Chem. 2020 Jul 1;197:112282. doi: 10.1016/j.ejmech.2020.112282. Epub 2020 Apr 15.
8
Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.阿尔茨海默病的药物重定位:在旧药物中寻找隐藏的线索。
J Alzheimers Dis. 2020;74(4):1013-1028. doi: 10.3233/JAD-200049.
9
Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer's Disease and Other Dementia Disorders.阿尔茨海默病和其他痴呆症患者缺血性卒中后的二级卒中预防。
J Alzheimers Dis. 2020;73(3):1013-1021. doi: 10.3233/JAD-191011.
10
Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool.丁酰胆碱酯酶:一个多方面的药理学靶点和工具。
Curr Protein Pept Sci. 2020;21(1):99-109. doi: 10.2174/1389203720666191107094949.